{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:18:32Z","timestamp":1791472712561,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation Projects","award":["No. 81671462"],"award-info":[{"award-number":["No. 81671462"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To construct chimeric antigen receptor (CAR)-T cells targeting epithelial cell adhesion molecule (EpCAM) antigen (anti-EpCAM-CAR-T).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A third-generation CAR-T cell construct used a single-chain variable fragment derived from monoclonal antibody against human EpCAM. Peripheral blood mononuclear cells were extracted from volunteers. The proportion of cluster of differentiation 8 positive (CD8+) and CD4\u2009+\u2009T cells was measured using flow cytometry. Western blot was used to detect the expression of EpCAM-CAR. The killing efficiency was detected using the MTT assay and transwell assay, and the secretion of killer cytokines tumour necrosis factor-\u03b1 (TNF-\u03b1) and interferon-\u03b3 (IFN-\u03b3) was detected using the ELISA. The inhibitory effect of EpCAM-CAR-T on colorectal cancer in vivo was detected using xenografts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      It was found that T cells expanded greatly, and the proportion of CD3+, CD8\u2009+\u2009and CD4\u2009+\u2009T cells was more than 60%. Furthermore, EpCAM-CAR-T cells had a higher tumour inhibition rate in the EpCAM expression positive group than in the negative group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The secretion of killer cytokines TNF-\u03b1 and IFN-\u03b3 in the EpCAM expression positive cell group was higher than that in the negative group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). In the experimental group treated with EpCAM-CAR-T cells, the survival rate of nude mice was higher (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), and the tumour was smaller than that in the blank and control groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). The secretion of serum killer cytokines TNF-\u03b1 and IFN-\u03b3 in tumour-bearing nude mice in the experimental group treated with EpCAM-CAR-T cells was higher than that in the blank and control groups (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study successfully constructed EpCAM-CAR cells and found that they can target and recognise EpCAM-positive tumour cells, secrete killer cytokines TNF-\u03b1 and IFN-\u03b3 and better inhibit the growth and metastasis of colorectal cancer in vitro and in vivo than unmodified T cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-024-03286-9","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T05:02:17Z","timestamp":1722920537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Siheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baofeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"2","key":"3286_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262.","journal-title":"CA Cancer J Clin"},{"key":"3286_CR2","doi-asserted-by":"publisher","unstructured":"Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014 Mar-Apr;64(2):104\u201317. https:\/\/doi.org\/10.3322\/caac.21220.","DOI":"10.3322\/caac.21220"},{"key":"3286_CR3","doi-asserted-by":"publisher","unstructured":"Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009 Nov-Dec;59(6):366\u201378. https:\/\/doi.org\/10.3322\/caac.20038.","DOI":"10.3322\/caac.20038"},{"key":"3286_CR4","doi-asserted-by":"publisher","unstructured":"Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012 Jul-Aug;62(4):220\u201341. https:\/\/doi.org\/10.3322\/caac.21149.","DOI":"10.3322\/caac.21149"},{"issue":"10","key":"3286_CR5","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479\u2013516. https:\/\/doi.org\/10.1093\/annonc\/mds236.","journal-title":"Ann Oncol"},{"key":"3286_CR6","doi-asserted-by":"publisher","unstructured":"Haraldsdottir S, Einarsdottir HM, Smaradottir A et al. Krabbamein \u00ed ristli og enda\u00fearmi [Colorectal cancer - review]. Laeknabladid. 2014;100(2):75\u201382. Icelandic. https:\/\/doi.org\/10.17992\/lbl.2014.02.531.","DOI":"10.17992\/lbl.2014.02.531"},{"issue":"1","key":"3286_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10151-008-0392-z","volume":"12","author":"KY Tan","year":"2008","unstructured":"Tan KY, Liu CB, Chen AH, et al. The role of traditional Chinese medicine in colorectal cancer treatment. Tech Coloproctol. 2008;12(1):1\u20136. https:\/\/doi.org\/10.1007\/s10151-008-0392-z. discussion 6.","journal-title":"Tech Coloproctol"},{"issue":"9","key":"3286_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jcyt.2013.02.007","volume":"15","author":"JJ Melenhorst","year":"2013","unstructured":"Melenhorst JJ, Levine BL. Innovation and opportunity for chimeric antigen receptor targeted T cells. Cytotherapy. 2013;15(9):1046\u201353. https:\/\/doi.org\/10.1016\/j.jcyt.2013.02.007.","journal-title":"Cytotherapy"},{"issue":"18","key":"3286_CR9","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133\u201341. https:\/\/doi.org\/10.1182\/blood-2011-12-400044.","journal-title":"Blood"},{"key":"3286_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","volume":"25","author":"AM Leen","year":"2007","unstructured":"Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243\u201365. https:\/\/doi.org\/10.1146\/annurev.immunol.25.022106.141527.","journal-title":"Annu Rev Immunol"},{"key":"3286_CR11","doi-asserted-by":"publisher","unstructured":"Tang HY, Cao YZ, Zhou YW et al. The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer. J Adv Res. 2024 Jan 18:S2090-1232(24)00027\u2009\u2013\u20094. https:\/\/doi.org\/10.1016\/j.jare.2024.01.014.","DOI":"10.1016\/j.jare.2024.01.014"},{"issue":"8","key":"3286_CR12","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1074\/jbc.M008839200","volume":"276","author":"JM Chong","year":"2001","unstructured":"Chong JM, Speicher DW. Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). J Biol Chem. 2001;276(8):5804\u201313. https:\/\/doi.org\/10.1074\/jbc.M008839200.","journal-title":"J Biol Chem"},{"issue":"16","key":"3286_CR13","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/0008-5472","volume":"64","author":"WA Osta","year":"2004","unstructured":"Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004;64(16):5818\u201324. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Cancer Res"},{"key":"3286_CR14","doi-asserted-by":"publisher","unstructured":"Dylla SJ, Beviglia L, Park IK et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One. 2008;3(6):e2428. https:\/\/doi.org\/10.1371\/journal.pone.0002428. Erratum in: PLoS ONE. 2008;3(8). https:\/\/doi.org\/10.1371\/annotation\/2aa6a20a-e63c-49b6-aeea-aae62435617f","DOI":"10.1371\/journal.pone.0002428 10.1371\/annotation\/2aa6a20a-e63c-49b6-aeea-aae62435617f"},{"issue":"2","key":"3286_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/cncr.22785","volume":"110","author":"P Zanna","year":"2007","unstructured":"Zanna P, Trerotola M, Vacca G, et al. Trop-1 are conserved growth stimulatory molecules that mark early stages of tumor progression. Cancer. 2007;110(2):452\u201364. https:\/\/doi.org\/10.1002\/cncr.22785.","journal-title":"Cancer"},{"issue":"1","key":"3286_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"PT Went","year":"2004","unstructured":"Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2003.08.026.","journal-title":"Hum Pathol"},{"issue":"21","key":"3286_CR17","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1200\/JCO.2007.15.8469","volume":"26","author":"JM Herman","year":"2008","unstructured":"Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503\u201310. https:\/\/doi.org\/10.1200\/JCO.2007.15.8469.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3286_CR18","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127(9):2209\u201321. https:\/\/doi.org\/10.1002\/ijc.25423.","journal-title":"Int J Cancer"},{"issue":"15","key":"3286_CR19","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3760\/cma.j.cn112137-20230810-00199","volume":"104","author":"YZ Cheng","year":"2024","unstructured":"Cheng YZ, Lian XR, Li HX, et al. [Relationship between gut microbiota and its metabolite dysregulation and postoperative cognitive dysfunction in elderly male C57BL\/6J mice after laparotomy exploration]. Zhonghua Yi Xue Za Zhi. 2024;104(15):1316\u201322. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20230810-00199. Chinese.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"3286_CR20","doi-asserted-by":"publisher","first-page":"110656","DOI":"10.1016\/j.intimp.2023.110656","volume":"122","author":"R Mirzaei","year":"2023","unstructured":"Mirzaei R, Shafiee S, Vafaei R, et al. Production of Novel recombinant anti-epcam antibody as targeted therapy for breast Cancer. Int Immunopharmacol. 2023;122:110656. https:\/\/doi.org\/10.1016\/j.intimp.2023.110656.","journal-title":"Int Immunopharmacol"},{"key":"3286_CR21","doi-asserted-by":"publisher","unstructured":"Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115\u201332. https:\/\/doi.org\/10.3322\/caac.21338.","DOI":"10.3322\/caac.21338"},{"key":"3286_CR22","doi-asserted-by":"publisher","unstructured":"Weitz J, Koch M, Debus J et al. Colorectal cancer. Lancet. 2005 Jan 8\u201314;365(9454):153\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(05)17706-X.","DOI":"10.1016\/S0140-6736(05)17706-X"},{"issue":"7","key":"3286_CR23","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00262-014-1650-8","volume":"64","author":"M Ai","year":"2015","unstructured":"Ai M, Curran MA. Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother. 2015;64(7):885\u201392. https:\/\/doi.org\/10.1007\/s00262-014-1650-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"3286_CR24","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2011.1592","volume":"306","author":"EA Engels","year":"2011","unstructured":"Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891\u2013901. https:\/\/doi.org\/10.1001\/jama.2011.1592.","journal-title":"JAMA"},{"issue":"4","key":"3286_CR25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687\u201392. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1860.","journal-title":"Clin Cancer Res"},{"key":"3286_CR26","doi-asserted-by":"publisher","first-page":"124187","DOI":"10.1155\/2012\/124187","volume":"2012","author":"G Zhou","year":"2012","unstructured":"Zhou G, Levitsky H. Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol. 2012;2012:124187. https:\/\/doi.org\/10.1155\/2012\/124187.","journal-title":"Clin Dev Immunol"},{"issue":"6024","key":"3286_CR27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"Science"},{"issue":"22","key":"3286_CR28","doi-asserted-by":"publisher","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"CM Kowolik","year":"2006","unstructured":"Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66(22):10995\u20131004. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0160.","journal-title":"Cancer Res"},{"issue":"24","key":"3286_CR29","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.1158\/1078-0432.CCR-07-4910","volume":"14","author":"PC Emtage","year":"2008","unstructured":"Emtage PC, Lo AS, Gomes EM, et al. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res. 2008;14(24):8112\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4910.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3286_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol. 2002;20(1):70\u20135. https:\/\/doi.org\/10.1038\/nbt0102-70.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"3286_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8\u2009+\u2009T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413\u201320. https:\/\/doi.org\/10.1038\/mt.2009.210.","journal-title":"Mol Ther"},{"issue":"3","key":"3286_CR32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","volume":"119","author":"DG Song","year":"2012","unstructured":"Song DG, Ye Q, Poussin M, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood. 2012;119(3):696\u2013706. https:\/\/doi.org\/10.1182\/blood-2011-03-344275.","journal-title":"Blood"},{"issue":"13","key":"3286_CR33","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","volume":"71","author":"DG Song","year":"2011","unstructured":"Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71(13):4617\u201327. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0422.","journal-title":"Cancer Res"},{"issue":"16","key":"3286_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"12","key":"3286_CR35","doi-asserted-by":"publisher","first-page":"e019321","DOI":"10.1136\/bmjopen-2017-019321","volume":"7","author":"EJM Grigor","year":"2017","unstructured":"Grigor EJM, Fergusson DA, Haggar F, et al. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. BMJ Open. 2017;7(12):e019321. https:\/\/doi.org\/10.1136\/bmjopen-2017-019321.","journal-title":"BMJ Open"},{"key":"3286_CR36","doi-asserted-by":"publisher","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","volume":"14","author":"M Hiltensperger","year":"2023","unstructured":"Hiltensperger M, Krackhardt AM. Current and future concepts for the generation and application of genetically Engineered Car-T and Tcr-T cells. Front Immunol. 2023;14:1121030. https:\/\/doi.org\/10.3389\/fimmu.2023.1121030.","journal-title":"Front Immunol"},{"issue":"18","key":"3286_CR37","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","volume":"127","author":"C Schwab","year":"2016","unstructured":"Schwab C, Ryan SL, Chilton L, et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood. 2016;127(18):2214\u20138. https:\/\/doi.org\/10.1182\/blood-2015-09-670166.","journal-title":"Blood"},{"issue":"6","key":"3286_CR38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.56.2025.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3286_CR39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1103849.","journal-title":"N Engl J Med"},{"issue":"16","key":"3286_CR40","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1215134.","journal-title":"N Engl J Med"},{"key":"3286_CR41","doi-asserted-by":"publisher","unstructured":"Walton ZE, Frigault MJ, Maus MV. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Expert Opin Pharmacother 2024 Apr 10:1\u201317. https:\/\/doi.org\/10.1080\/14656566.2024.2340738.","DOI":"10.1080\/14656566.2024.2340738"},{"issue":"4","key":"3286_CR42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351. https:\/\/doi.org\/10.1038\/mt.2010.24.","journal-title":"Mol Ther"},{"issue":"3","key":"3286_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/cgt.2011.83","volume":"19","author":"N Rainusso","year":"2012","unstructured":"Rainusso N, Brawley VS, Ghazi A, et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 2012;19(3):212\u20137. https:\/\/doi.org\/10.1038\/cgt.2011.83.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"3286_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.smim.2015.11.003","volume":"28","author":"PA Beavis","year":"2016","unstructured":"Beavis PA, Slaney CY, Kershaw MH, et al. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin Immunol. 2016;28(1):64\u201372.","journal-title":"Semin Immunol"},{"issue":"10","key":"3286_CR45","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00262-012-1245-1","volume":"61","author":"S Sapoznik","year":"2012","unstructured":"Sapoznik S, Ortenberg R, Galore-Haskel G, et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother. 2012;61(10):1833\u201347. https:\/\/doi.org\/10.1007\/s00262-012-1245-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"26","key":"3286_CR46","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, et al. Regression of Glioblastoma after chimeric Antigen receptor T-Cell therapy. N Engl J Med. 2016;375(26):2561\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1610497.","journal-title":"N Engl J Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03286-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03286-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03286-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T05:06:52Z","timestamp":1722920812000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03286-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03286-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations and reported in accordance with ARRIVE guidelines. All donors were informed and signed an informed consent form. The study was approved by the Ethics Committee of Hainan West Central Hospital and Mice maintenance and treatments described were approved by the Ethics Committee of Hainan West Central Hospital (Approval number: SH9H-2022-AB74-SB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All of the authors had no any personal, financial, commercial, or academic conflicts of interest separately.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"249"}}